Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Alnylam, Anthos, Arbutus, Bridgebio, Cybin, Eli Lilly, Intellia, Neurogene.
New hires and promotions in the biopharma industry, including: Alterity, Byondis, Cancervax, Georgiamune, Kaida, Kuros, Latigo, LB, Mind Medicine, Mirai, Nanovation, Terns.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aldeyra, Avenzo, HCW, Neurobo, Trogenix, VBI Vaccines, Velavigo, WY Biotech.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Alentis, Alkeus, Arrowhead, Astrazeneca, Biogen, Formycon, Foundation Medicine, Johnson, Klinge, Junshi, Orphelia, Samsung Bioepis, Syndax, Vaderis, Topalliance.
Neurogene Inc.’s stock sank 43% on news that its phase I/II gene therapy, NGN-401, resulted in a serious adverse event in a pediatric Rett syndrome patient receiving the highest dose.
Patients infected with hepatitis C have had the ability to rid their livers of the virus for some time, while patients with chronic hepatitis B virus infection have been required to take medications for the rest of their lives in the hopes of just dampening damage to the liver caused by the virus. But, at The Liver Meeting 2024, Arbutus presented data from the phase IIa Im-prove study suggesting a cure might be on its way with its DNAi drug, which binds to the viral mRNA promoting its cutting, leading to loss of translation of the viral proteins.
With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in a potential $745 million collaboration aimed at developing a somatostatin receptor 2 radiotherapeutic for cancer.
Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion another $900 million. The two assets are BSI-045B, a high affinity and high potency anti-TSLP monoclonal antibody, and BSI-502, a bispecific antibody directed against TSLP and IL4R.
Syndax Pharmaceuticals Inc. won U.S. FDA approval – the company’s second this year – for menin inhibitor Revuforj (revumenib) with a black box warning for differentiation syndrome. “We’ve long expected that would be the case,” said CEO Michael Metzger. For “the last six years or so” the agency has had a “heightened awareness” of the problem, and he predicted all drugs in the class would bear similar cautionary language. But there’s also a warning about QT prolongation and a requirement for monitoring.
RSS
